Q2 Highlights:
- Company announces plans for the Phase I first-in-human study to be undertaken in Australia
with commencement expected in Q4
- Manufacturing of the MagSenseTM HER2 nanoparticle formulation for use in a first in human
study has proceeded on plan
- Cash balance of $4.2M at 30 June 2020; subsequent to 30 June additional $4.7M received (net
of costs) from oversubscribed placement
- Additional funding provides capital to support company beyond Phase I study completion
and accelerate additional product plans
- Di Angus appointed non-executive Director
Read the Quarterly Activity Report and Appendix C.